SG52739A1 - Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds - Google Patents

Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds

Info

Publication number
SG52739A1
SG52739A1 SG1996008590A SG1996008590A SG52739A1 SG 52739 A1 SG52739 A1 SG 52739A1 SG 1996008590 A SG1996008590 A SG 1996008590A SG 1996008590 A SG1996008590 A SG 1996008590A SG 52739 A1 SG52739 A1 SG 52739A1
Authority
SG
Singapore
Prior art keywords
compounds
selenopyrimidinone
thiapyrimidinone
disclosed
antiproliferative
Prior art date
Application number
SG1996008590A
Other languages
English (en)
Inventor
Michael D Varney
William H Romines
Cynthia L Palmer
Judith G Deal
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of SG52739A1 publication Critical patent/SG52739A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG1996008590A 1992-12-16 1993-12-10 Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds SG52739A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99125992A 1992-12-16 1992-12-16

Publications (1)

Publication Number Publication Date
SG52739A1 true SG52739A1 (en) 1998-09-28

Family

ID=25537030

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996008590A SG52739A1 (en) 1992-12-16 1993-12-10 Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds

Country Status (13)

Country Link
US (5) US5739141A (fr)
EP (1) EP0674516B1 (fr)
JP (1) JPH08504765A (fr)
AT (1) ATE189390T1 (fr)
AU (1) AU5846494A (fr)
CA (1) CA2151588C (fr)
DE (1) DE69327796T2 (fr)
DK (1) DK0674516T3 (fr)
ES (1) ES2145122T3 (fr)
GR (1) GR3033314T3 (fr)
PT (1) PT674516E (fr)
SG (1) SG52739A1 (fr)
WO (1) WO1994013295A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52739A1 (en) 1992-12-16 1998-09-28 Agouron Pharma Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
US5945427A (en) * 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
US5594139A (en) * 1993-01-29 1997-01-14 Agouron Pharmaceuticals, Inc. Processes for preparing antiproliferative garft-inhibiting compounds
US5608082A (en) * 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
CN1053448C (zh) * 1994-07-28 2000-06-14 阿格罗尼制药公司 用作抗增殖药物及garft抑制剂的化合物
DE69432801T2 (de) * 1994-07-28 2003-12-04 Agouron Pharmaceuticals, Inc. Verbindungen die als antiproliferierende mittel und garft inhibitoren verwendbar sind
US5831100A (en) * 1995-06-07 1998-11-03 Agouron Pharmaceuticals, Inc. Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates
AUPO227896A0 (en) * 1996-09-13 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Novel compounds and their preparation
BR9909418A (pt) * 1998-03-27 2001-09-25 Genentech Inc Antagonistas para o tratamento de distúrbios mediados por receptor de aderência cd11/cd18 e método para tratar ou melhorar uma resposta ou distúrbio imunológico ou inflamatório em um mamìfero mediada através da famìlia cd11/cd18 em moléculas de aderência celular
EP1109560B1 (fr) * 1998-09-04 2003-08-27 Agouron Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs d'aicarft
US6423720B1 (en) 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
EP1601969A2 (fr) 2003-03-08 2005-12-07 Auvation Ltd Marqueurs cancereux
CA2602291C (fr) 2005-03-28 2015-08-11 Pericor Therapeutics, Inc. Traitements pour la prevention ou la reduction d'effets indesirables chez un patient ayant une diminution de la fonction ventriculaire gauche
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (fr) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Procédés, compositions et formulations pour prévenir ou réduire les effets indésirables chez un patient
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US7705001B2 (en) 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
AU2009244535A1 (en) 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives
US7985765B2 (en) 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
CA2739463C (fr) * 2008-10-03 2018-07-03 Pericor Therapeutics, Inc. Procedes et compositions pour le traitement de l'insuffisance cardiaque aigue
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
JP6379296B2 (ja) * 2014-12-02 2018-08-22 イーライ リリー アンド カンパニー １−オキソ−１，２−ジヒドロイソキノリン−７−イル−（５−置換−チオフェン−２−イル）−スルホンアミド化合物、それらの化合物を含む製剤、がん治療におけるａｉｃａｒｆｔ阻害剤としてのそれらの使用
DE102017221259A1 (de) * 2017-11-28 2019-05-29 Evonik Degussa Gmbh Silanmischungen und Verfahren zu deren Herstellung
CN112321425B (zh) * 2020-10-23 2022-08-09 上海毕得医药科技股份有限公司 一种4-(3-溴丙基)苯甲酸甲酯的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3222914A1 (de) * 1982-06-18 1983-12-22 Beiersdorf Ag, 2000 Hamburg Substituierte 5-phenylthio-6-amino-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
US4871743A (en) * 1988-01-19 1989-10-03 The Trustees Of Princeton University L-glutamic acid derivatives
EP0341837A3 (fr) * 1988-04-15 1990-08-16 The Wellcome Foundation Limited Dérivés d'acide glutamique
US4971973A (en) * 1989-05-17 1990-11-20 Burroughs Wellcome Co. Glutamic acid derivatives
US4921836A (en) * 1989-05-17 1990-05-01 Burroughs Wellcome Co. Substituted glutamic acids
US4920125A (en) * 1989-08-29 1990-04-24 The Trustees Of Princeton University L-glutamic acid derivatives
US5013738A (en) * 1990-04-18 1991-05-07 The Trustees Of Princeton University L-glutamic acid derivatives
AU642753B2 (en) * 1990-07-24 1993-10-28 Mitsubishi Petrochemical Company Limited Halogen-containing compounds, herbicidal composition containing the same as an active ingredient, and intermediary compounds therefor
SG52739A1 (en) 1992-12-16 1998-09-28 Agouron Pharma Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
US5945427A (en) 1995-06-07 1999-08-31 Agouron Pharmaceuticals, Inc. Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives

Also Published As

Publication number Publication date
WO1994013295A1 (fr) 1994-06-23
US20020173515A1 (en) 2002-11-21
US20010018443A1 (en) 2001-08-30
EP0674516A4 (fr) 1995-10-25
CA2151588A1 (fr) 1994-06-23
EP0674516A1 (fr) 1995-10-04
ATE189390T1 (de) 2000-02-15
GR3033314T3 (en) 2000-09-29
JPH08504765A (ja) 1996-05-21
US6323210B2 (en) 2001-11-27
ES2145122T3 (es) 2000-07-01
US5726312A (en) 1998-03-10
DE69327796T2 (de) 2000-06-21
US6207670B1 (en) 2001-03-27
CA2151588C (fr) 2002-03-19
EP0674516B1 (fr) 2000-02-02
DK0674516T3 (da) 2000-07-24
AU5846494A (en) 1994-07-04
DE69327796D1 (de) 2000-03-09
PT674516E (pt) 2000-05-31
US5739141A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
SG52739A1 (en) Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
BG101833A (en) Guanine derivative
ZA955466B (en) Stereochemical wortmannin derivatives
TW225534B (fr)
AU8581991A (en) Mercaptoacetylamide derivatives as inhibitors of enkephalinase and ACE, and processes for their production
TW327172B (en) Novel mercaptoacetylamide bicyclic lactam derivatives
AU2769995A (en) Bicyclic lactam inhibitors of interleukin-1-beta converting enzyme
IL125285A0 (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and pharmaceutical compositions containing the same
EP0123950A3 (fr) Intermédiaires pour la thymosine alpha 1 et pour la désacéthylthymosine alpha 1
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
MX9801190A (es) Inhibidores de prolil endopeptidasa.
CA2166692A1 (fr) Nouveaux nucleosides 9-n-bicycliques, agents utiles comme inhibiteurs selectifs pour les cytokines pro-inflammatoires
CA2154668A1 (fr) Derives d'acide glutamique heterocyclique de condensation, agents antiproliferatifs
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
ES8205126A1 (es) Un procedimiento para la preparacion de un inhibidor del enzima convertidor de la angiotensina.
SG44827A1 (en) Compounds useful as antiproliferative agents and garft inhibitors
AP9400608A0 (en) "New nicotinic acid derivative".
TW327175B (en) Process for preparing steroidal 3,5-diene-3-carboxylic acid derivatives
MX9704677A (es) Procedimientos novedosos para preparar intermediarios de inhibidores de encefalinasa y enzima de conversion a angiotensina y sus intermediarios.
MX9500363A (es) Monohiddrato de (e)-2'-desoxi-2'- (fluorometilen) citidina.
ES8605867A1 (es) Procedimiento para la obtencion de capas de nitruro de tita-nio doradas
TW243453B (en) Cloning and characterization of a cardiac adenylyl cyclase
TW271382B (en) Process of producing soy sauce added with spirulina
HU9500944D0 (en) N,n-substituted amino-methylen-imidazolinone derivatives as intermediates of 2-substituted 5-chloro-imidazol-4-carbaldeydes